Legend Biotech's CAR-T Therapy Generates $157 Million in Q1 Sales

On April 17, Hengrui Pharma released its 2023 annual report and Q1 2024 report.

In 2023, the company achieved operating revenue of 22.82 billion yuan, representing a year-on-year increase of 7.26%; net profit attributable to shareholders of the listed company was 4.302 billion yuan, marking a year-on-year increase of 10.14%. In 2023, Hengrui Pharma's total capitalized R&D expenses amounted to 1.196 billion yuan.

In the first quarter of 2024, the company achieved operating revenue of 5.997 billion yuan, a year-on-year increase of 9.2%; net profit attributable to shareholders of the listed company was 1.370 billion yuan, a year-on-year increase of 10.48%. What do you think of Hengrui Pharma's performance?

Legend Biotech's CAR-T Therapy Sales Continue to Grow.

On April 16, Johnson & Johnson released its Q1 2024 earnings report. The report noted that CARVYKTI, developed in collaboration with Legend Biotech, generated approximately US$157 million in net trade sales during the quarter.

In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you through them.

1. Market Express

1) Legend Biotech's CAR-T Therapy Q1 Sales Reach $157 Million

On April 16, Johnson & Johnson released its Q1 2024 earnings report. The report noted that CARVYKTI, developed in collaboration with Legend Biotech, generated approximately US$157 million in net trade sales during the quarter.

2. Capital Information

1) Hengrui Pharma Announces 2023 Financial Report

On April 17, Hengrui Pharma released its 2023 financial report. During the reporting period, the company achieved operating revenue of 22.82 billion yuan, a year-on-year increase of 7.26%; net profit attributable to shareholders of listed companies was 4.302 billion yuan, a year-on-year increase of 10.14%. In 2023, the total capitalized R&D expenses of Hengrui Pharma amounted to 1.196 billion yuan.

2) Hengrui Pharma's Q1 Revenue Grows by 9.2%

On April 17, Hengrui Pharma released its Q1 2024 financial report. During the reporting period, the company achieved operating revenue of 5.997 billion yuan, a year-on-year increase of 9.2%; net profit attributable to shareholders of the listed company was 1.370 billion yuan, a year-on-year increase of 10.48%.

3. Pharma Device Updates

1) TISA-818 Mouthwash by Aitia Approved for Clinical Use

On April 17, according to the CDE official website, Iteria TISA-818 Mouthwash was approved for clinical trials, aiming to conduct research on the treatment of oral mucositis.

2) Haisco HSK16149 Capsule Approved for Clinical Trials

On April 17, according to the CDE official website, Haisco's HSK16149 capsule has been approved for clinical trials, intended for the treatment of fibromyalgia.

3) Sanofi's Frexalimab Injection Approved for Clinical Use

On April 17, according to the CDE website, Sanofi's Frexalimab Injection has been approved for clinical trials, intended for the treatment of adult relapsing multiple sclerosis (RMS).

4) Hanyu Pharma's Semaglutide Injection Approved for Clinical Use

On April 17, according to the CDE official website, Hanmi Pharmaceuticals' semaglutide injection was approved for clinical trials, intended for weight management in adult patients with obesity or overweight and at least one weight-related comorbidity.

5) Anaerobic organism KAL-002 approved for clinical trials

On April 17, according to the CDE official website, Anaerobio's KAL-002 has been approved for clinical trials, intended for chemotherapy-related diarrhea and radiation-induced enteritis.

6) Henlius HLX53 Approved for Clinical Trials

On April 17, according to the CDE website, Henlius' HLX53 was approved for clinical trials, proposed for first-line treatment of locally advanced or metastatic hepatocellular carcinoma in combination with serplulimab injection and bevacizumab injection.

7) Akeso Biopharma's AK117 Injection Approved for Clinical Trials

On April 17, according to the CDE official website, Akeso Biopharma's AK117 injection has been approved for clinical trials. It is intended to be used as a monotherapy or in combination with AK117 to treat relapsed or refractory classical Hodgkin lymphoma that has failed PD-1/L1 inhibitor treatment.

8) Hengyi Bio HPP737 Capsule Approved for Clinical Trials

On April 17, according to the CDE official website, Hengyi Bio's HPP737 capsule was approved for clinical trials, intended for the study of idiopathic pulmonary fibrosis.

9) Chia Tai Tianqing's TQB3702 Tablets Approved for Clinical Trials

On April 17, according to the CDE official website, Zhengda Tianqing's TQB3702 tablet has been approved for clinical trials, intended for use in systemic lupus erythematosus.

10) Ascentage Pharma's APG-2575 Tablets Approved for Clinical Trials

On April 17, according to the CDE official website, Ascentage Pharma's APG-2575 tablets have been approved for clinical trials. They are intended to be used in combination with Acalabrutinib to treat adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have previously received Bruton’s tyrosine kinase (BTK) inhibitor therapy.

11) JACOB's KRASG12C inhibitor glecirasib receives orphan drug designation for pancreatic cancer indication in the United States

On April 17, JACOBIO announced that the KRASG12C inhibitor glecirasib received orphan drug designation for pancreatic cancer indication in the United States.

12) JAK Inhibitor Introduced by Pharmstandard Approved for Marketing in Macao, China

On April 16, Pharmstandard announced that the JAK inhibitor Ruxolitinib Phosphate Cream has been approved for marketing in Macao, China, for the treatment of non-segmental vitiligo with facial involvement in adolescents aged 12 years and older and adults.

13) Health Yuan TG-1000 Capsule Phase III Clinical Trial Reaches Primary Endpoint

On April 17, Health Yuan announced that recently, the multi-center Phase III clinical trial of the company's innovative drug product TG-1000 capsule for uncomplicated acute infections of simple Influenza A and B in patients aged 12 years and above has reached the primary endpoint.

14) Jiuchuang Biotech Rh Blood Group Typing Card (Microcolumn Gel Method) Obtains Medical Device Registration Certificate

On April 17, Jiuyuan Bio announced that the company received the "Medical Device Registration Certificate" issued by the National Medical Products Administration on April 17, 2024. The product name is Rh Blood Group Typing Card (Microcolumn Gel Method). This product is used for detecting D, C, c, E, and e antigens in the Rh blood group system and is only used for clinical testing, not for blood source screening.

4. Overseas Pharmaceutical News

1) Takeda Pharmaceutical and Kumquat Biosciences Reach Strategic Collaboration Agreement

On April 16, Kumquat Biosciences announced an exclusive strategic collaboration with Takeda to co-develop novel immuno-oncology (I/O) small molecule inhibitors and commercialize them as monotherapies and/or combination therapies. Under the terms of the agreement, Kumquat granted Takeda an exclusive, global, royalty-bearing license to develop and commercialize selected small molecule inhibitors.

2) AbbVie Reaches Cooperation Agreement with Medicell

On April 16, AbbVie announced a collaboration agreement with Medicell to develop six drugs for different indications using the latter's long-acting technology platform. For this, AbbVie needs to pay a $35 million upfront payment, up to $1.9 billion in milestone payments, and mid-single-digit to low-double-digit percentage royalties on sales.

Editor: Bai Ji

Disclaimer: This article is a reprint from PharmNet. The images and text are the original property of the author, and the purpose of the reprint is to convey more information. It does not represent the views of this platform. If there are any issues regarding the content, copyright, or other aspects, please leave a message on this platform, and we will address it promptly.